A molecular characterization of the NTR hexapeptide binding with the full-length peptide is therefore crucial towards understanding of the aggregation-inhibitive and neuroprotective properties of those short peptides, which is useful for introducing new AD therapy. Here, NTSR1 is linked to Alzheimer disease.